| Literature DB >> 33262599 |
María Noelia Alonso1,2, Tatiana Mata-Forte3, Natalia García-León2,4, Paula Agostina Vullo2,5, Germán Ramirez-Olivencia3, Miriam Estébanez3, Francisco Álvarez-Marcos6.
Abstract
AIM: In addition to its respiratory impact of SARS-CoV2, skin lesions of probable vascular origin have been described. This study intends to quantify the incidence of acro-ischemic lesions in COVID-19 infected adult subjects in our population, describing clinical patterns and associated findings.Entities:
Keywords: COVID-19; Raynaud´s phenomenon; acro-ischemia; hypercoagulability; ischemia reperfusion injury; thromboinflammation
Mesh:
Year: 2020 PMID: 33262599 PMCID: PMC7699992 DOI: 10.2147/VHRM.S276530
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Figure 1Clinical patterns of acroischemia. Upper: Outpatients (ARP and PP). Lower: Hospitalized patients (SMI and AO).
Demographic Characteristics of Patients with COVID-19 Infection and Acro-Ischemia
| Demographic Characteristics | Atypical Raynaud Phenomenon (n=4) | Pseudo-Pernio (n=5) | Severe Microcirculatory Ischemia with Preserved Pulse (n=6) | Dry Gangrene with Arteriosclerosis Obliterans (n=9) |
|---|---|---|---|---|
| Age; yr (mean±standard deviation) | 45±5 | 44±25 | 78±19 | 70±10 |
| Race (caucasian:hispanic) | 4:0 | 5:0 | 5:1 | 9:0 |
| Sex (female:male) | 3:1 | 2:3 | 0:6 | 2:7 |
| Covid-19 environment (%) | ||||
| Health workers | 3/4 | 3/5 | UK | UK |
| Nursing home | – | 1/5 | UK | UK |
| Other | 1/4 | 1/5 | UK | UK |
| Number of tests done:positive results | ||||
| PCR | 4:2 | 5:3 | 6:5 | 9:8 |
| Serological | 2:0 | 1:0 | – | – |
| CV risk factor (%, count) | ||||
| Tobacco use | 0 | 0 | 17 (n=1) | 44 (n=4) |
| HBP | 25 (n=1) | 20 (n=1) | 83 (n=5) | 89 (n=8) |
| Obesity | 0 | 0 | 17 (n=1) | 78 (n=7) |
| Dyslipidemia | 0 | 20 (n=1) | 50 (n=3) | 67 (n=6) |
| Diabetes mellitus | 0 | 0 | 17 (n=1) | 67 (n=6) |
| COPD | 0 | 0 | 33 (n=2) | 11 (n=1) |
| Medical history (%) | 0 | 0 | 17 | 22 |
| Cancer | 0 | 0 | 17 | 22 |
| Venous thromboembolism | 0 | 0 | 33 | 0 |
| Cardiovascular disease | 0 | 0 | 50 | 55 |
| Cerebrovascular disease | 0 | 0 | 0 | 11 |
| Autoimmune disease | 0 | 0 | 0 | 0 |
| Charlson comorbidity index (%) | ||||
| 0–1 | – | – | 67 | 22 |
| ≤ 2 | – | – | 0 | 55 |
| > 3 | – | – | 33 | 22 |
| Previous treatment (%) | ||||
| ACE inhibitor | 25 | 20 | 83 | 89 |
| Statin | 0 | 20 | 50 | 67 |
| Antiplatelet | 0 | 0 | 33 | 55 |
| Anticoagulant | 0 | 0 | 33 | 11 |
Abbreviations: ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HBP, hypertension; PCR, polymerase chain reaction; UK, unknown.
Clinical Characteristics of Patients with COVID-19 Infection and Acro-Ischemia (I)
| Clinical Characteristics | Atypical Raynaud Phenomenon (n=4) | Pseudo-Pernio (n=5) | Severe Microcirculatory Ischemia with Preserve Pulse (n=6) | Dry Gangrene with Arteriosclerosis Obliterans (n=9) |
|---|---|---|---|---|
| Type of patient | ||||
| Outpatients | 4 | 5 | 0 | 0 |
| Hospital: ward | 0 | 0 | 6 | 1 |
| Hospital: critical care | 0 | 0 | 0 | 8 |
| Covid-19 symptoms (%) | ||||
| Fever | 100 | 100 | 100 | 100 |
| Malaise | 100 | 100 | 100 | 100 |
| Cough | 100 | 100 | 100 | 100 |
| Diarrhea | 75 | 100 | 100 | 100 |
| Headache | 100 | 80 | 100 | 100 |
| Hyposmia | 50 | 0 | 50 | 55 |
| Dysgeusia | 50 | 40 | 50 | 67 |
| Others symptoms (%) | ||||
| Arthralgia | 25 | 40 | 50 | 55 |
| Loin pain | 50 | 0 | 0 | 0 |
| Otalgia | 25 | 0 | 0 | 0 |
| Lymphadenopathy | 25 | 20 | 0 | 0 |
| Genitalia (ulcer) | 25 | 0 | 0 | 0 |
| Viral pneumonia (%) | 0 | 0 | 100 | 100 |
| Disease severity (%) | ||||
| Mild | 100 | 100 | – | – |
| Moderate | – | – | 33 | – |
| Severe | – | – | 67 | 100 |
| CURB-65 score 2 (%) | 67 | 77 | ||
| SaO2/FiO2 | – | – | >140 | <140 |
| Covid-19 treatment (%) | ||||
| Hydroxychloroquine | – | – | 100 | 100 |
| Lopinavir/Ritonavir | – | – | 67 | 77 |
| Interferon | – | – | 50 | 77 |
| Glucocorticoids | – | – | 83 | 55 |
| Tocilizumab | – | – | – | 22 |
| Cyclosporine | – | – | – | 22 |
| Colchicine | – | – | – | 11 |
| LMWH before skin event (%) | ||||
| Prophylactic doses | – | – | 50 | 44 |
| Medium doses | – | – | 16,7 | 22 |
| High doses | – | – | 33 | 33 |
| Skin event treatment (%) | ||||
| Antiplatelet | 25 | 20 | 17 | 22 |
| Anticoagulant | 0 | 0 | 100 | 100 |
| Statin | 0 | 40 | 17 | 22 |
Clinical Characteristics of Patients with COVID-19 Infection and Acro-Ischemia (II)
| Clinical Characteristics | Atypical Raynaud Phenomenon (n=4) | Pseudo-Pernio (n=5) | Severe Microcirculatory Ischemia with Preserve Pulse (n=6) | Dry Gangrene with Arteriosclerosis Obliterans (n=9) |
|---|---|---|---|---|
| Days from disease onset to vascular skin event | 13 (10–14) | 13 (10–14) | 20 (6–24) | 14 (11–18) |
| Skin lesions duration ( | 15 minutes pulses (7–14) | 10 days (2–14) | 28 days (21–59) | unresolved |
| Other vascular skin lesions (%) | ||||
| Splinter hemorrhage | – | – | 17 | – |
| Livedo racemosa | – | – | – | 33 |
| Ischemic events (%) | ||||
| Cardiac | – | – | 17 | 44 |
| Brain | – | – | 67 | 22 |
| Retina | – | 20 | – | – |
| Spleen | – | – | – | 11 |
| Gut | – | – | – | 22 |
| Nerve | – | – | – | 22 |
| Acute kidney injury (%) | – | – | 0 | 100 |
| Liver failure (%) | – | – | 0 | 33 |
| VTE (%) | – | – | 0 | 22 |
| Atrial fibrillation (%) | – | – | 33 | 22 |
| Syncope (%) | – | – | 50 | 44 |
| Bacterial superinfection (%) | – | – | 0 | 44 |
| SOFA | 0 | 0 | ≤ 2 | >2 |
| Exitus (%) | – | – | 17 | 67 |
| Discharged (%) | – | – | 67 | 11 |
| Readmission (%) | – | – | 0 | 0 |
| Follow-up, days | 38 | 19 | 44 | 54 |
Figure 2Fundus autofluorescence: abnormalities in branches of central retinal artery.
Figure 3MRI: femoral condyle ischemia.
Figure 4CT-scan: Thalamic infarct.
Figure 599mTc macroaggregated albumin pulmonary perfusion scan: change in regional pulmonary perfusion as a result of posture. Lower lobes are affected by gravity.
Figure 6Pathophysiological hypothesis and clinical-demographic phenotypes of COVID-19 infection. CVRF: Cardiovascular Risk Factors.